BUSINESS ACQUISITIONS (Tables)

12 Months Ended

Dec. 31, 2024

Business Combinations [Abstract]

Schedule of Pro Forma Information

The following unaudited pro forma combined financial information reflects the consolidated statement of operations of the Company as if the acquisition of LifeLabs had occurred as of January 1, 2023. The pro forma information includes adjustments primarily related to the amortization of acquired intangible assets (see below), interest expense associated with debt of LifeLabs which was extinguished prior to the acquisition, interest expense associated with senior notes issued to fund the acquisition (see Note 13), the impact on depreciation expense of recording acquired property, plant and equipment at fair value (see below), and transaction costs related to the LifeLabs acquisition. The pro forma combined financial information does not include the estimated annual synergies expected to be realized upon completion of the integration of LifeLabs and therefore is not indicative of the results of operations as they would have been had the transaction been effected on the assumed date.

	Year Ended December 31,
	2024		2023
Pro forma net revenues	$	10,320	$	9,917
Pro forma net income attributable to Quest Diagnostics	$	869	$	842
Pro forma earnings per share attributable to Quest Diagnostics' common stockholders:
Basic	$	7.76	$	7.47
Diluted	$	7.67	$	7.38

Schedule of Purchase Price Allocation

The following table provides a preliminary summary of the assets acquired and liabilities assumed, which may be revised as additional information becomes available during the measurement period.

	LifeLabs		Laboratory Business of Three Physician Groups in New York		Select Assets of the Outreach Laboratory Services Business of Allina Health		Select Assets of the Outreach Laboratory Services Business of OhioHealth		Outreach Laboratory Services Business of University Hospitals		Other Acquisitions (a)		Total
Cash and cash equivalents	$	50	$	—	$	—	$	—	$	—	$	—	$	50
Accounts receivable	31		—		—		—		—		—		31
Other current assets	23		—		—		—		—		2		25
Property, plant and equipment	250		—		—		—		—		4		254
Finance lease assets (recorded in property, plant and equipment)	—		—		—		—		—		17		17
Operating lease right-of-use assets	65		—		—		—		—		17		82
Goodwill	303		243		175		146		125		154		1,146
Intangible assets	434		57		55		54		58		95		753
Other assets	39		—		—		—		—		—		39
Total assets acquired	1,195		300		230		200		183		289		2,397
Accounts payable and accrued expenses	66		—		—		—		—		—		66
Current portion of long-term operating lease liabilities	14		—		—		—		—		4		18
Finance lease liabilities (recorded in long-term debt)	—		—		—		—		—		17		17
Long-term operating lease liabilities	51		—		—		—		—		13		64
Other liabilities	11		—		—		—		—		7		18
Total liabilities assumed	142		—		—		—		—		41		183
Net assets acquired	$	1,053	$	300	$	230	$	200	$	183	$	248	$	2,214

(a) Principally relates to the acquisitions of Lenco and PathAI Diagnostics.

Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination

The preliminary fair values of the acquired intangible assets are as follows:

	LifeLabs		Laboratory Business of Three Physician Groups in New York		Select Assets of the Outreach Laboratory Services Business of Allina Health		Select Assets of the Outreach Laboratory Services Business of OhioHealth		Outreach Laboratory Services Business of University Hospitals		Other Acquisitions (a)		Total		Weighted Average Useful Life (in years)
Customer-related	$	335	$	57	$	55	$	54	$	43	$	95	$	639	15 - 25
Trade names	99		—		—		—		—		—		99		15
Non-competition agreements	—		—		—		—		15		—		15		5
	$	434	$	57	$	55	$	54	$	58	$	95	$	753

(a) Principally relates to the acquisitions of Lenco and PathAI Diagnostics.